Advanced search
Publication Cover
Emerging Microbes & Infections Volume 9, 2020 - Issue 1
Submit an article Journal homepage
1,597
Views
1
CrossRef citations to date
0
Altmetric
Letter

An adult case of invasive pneumococcal disease due to serotype 12F-specific polysaccharide antibody failure following a 23-valent polysaccharide vaccination

Yasuhiro Tanakaa Department of Respiratory Medicine, Nagasaki University Hospital, Nagasaki City, Japan;b Department of Respiratory Medicine, Sasebo City General Hospital, Sasebo City, JapanView further author information
,
Kazuko Yamamotoa Department of Respiratory Medicine, Nagasaki University Hospital, Nagasaki City, Japan;c Infection Control and Education Center, Nagasaki University Hospital, Nagasaki City, JapanCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-1357-1676View further author information
ORCID Icon,
Yuichi Fukudab Department of Respiratory Medicine, Sasebo City General Hospital, Sasebo City, JapanView further author information
,
Asuka Umemurab Department of Respiratory Medicine, Sasebo City General Hospital, Sasebo City, JapanView further author information
,
Masataka Yoshidab Department of Respiratory Medicine, Sasebo City General Hospital, Sasebo City, JapanView further author information
,
Shuhei Ideguchia Department of Respiratory Medicine, Nagasaki University Hospital, Nagasaki City, JapanView further author information
,
Nobuyuki Ashizawaa Department of Respiratory Medicine, Nagasaki University Hospital, Nagasaki City, JapanView further author information
,
Tatsuro Hirayamaa Department of Respiratory Medicine, Nagasaki University Hospital, Nagasaki City, JapanView further author information
,
Masato Tashiroc Infection Control and Education Center, Nagasaki University Hospital, Nagasaki City, JapanView further author information
,
Takahiro Takazonoa Department of Respiratory Medicine, Nagasaki University Hospital, Nagasaki City, JapanView further author information
,
Yoshifumi Imamuraa Department of Respiratory Medicine, Nagasaki University Hospital, Nagasaki City, JapanView further author information
,
Taiga Miyazakia Department of Respiratory Medicine, Nagasaki University Hospital, Nagasaki City, JapanView further author information
,
Koichi Izumikawac Infection Control and Education Center, Nagasaki University Hospital, Nagasaki City, JapanView further author information
,
Katsunori Yanagiharad Department of Laboratory Medicine, Nagasaki University Hospital, Nagasaki City, JapanView further author information
,
Bin Change Department of Bacteriology I, National Institute of Infectious Diseases, Shinjuku City, JapanView further author information
&
Hiroshi Mukaea Department of Respiratory Medicine, Nagasaki University Hospital, Nagasaki City, JapanView further author information
 show all
Pages 2266-2268 | Received 03 Aug 2020, Accepted 26 Sep 2020, Published online: 14 Oct 2020

References

  • Burton RL, Nahm MH. Development and validation of a fourfold multiplexed opsonization assay (MOPA4) for pneumococcal antibodies. Clin Vaccine Immunol. 2006 Sep;13(9):1004–1009.
  • Tamura K, Matsubara K, Ishiwada N, et al. Hyporesponsiveness to the infecting serotype after vaccination of children with seven-valent pneumococcal conjugate vaccine following invasive pneumococcal disease. Vaccine. 2014 Mar 14;32(13):1444–1450.
  • Henckaerts I, Durant N, De Grave D, et al. Validation of a routine opsonophagocytosis assay to predict invasive pneumococcal disease efficacy of conjugate vaccine in children. Vaccine. 2007 Mar 22;25(13):2518–2527.
  • Organization WH. WHO/health Canada Consulation on serological criteria for evaluation and licensing of new pneumococcal vaccines. Ottawa. Canada (Tor). 2008.
  • Oishi T, Ishiwada N, Matsubara K, et al. Low opsonic activity to the infecting serotype in pediatric patients with invasive pneumococcal disease. Vaccine. 2013 Jan 21;31(5):845–849.
  • Rokney A, Ben-Shimol S, Korenman Z, et al. Emergence of Streptococcus pneumoniae serotype 12F after sequential introduction of 7- and 13-valent vaccines, Israel. Emerg Infect Dis. 2018 Mar;24(3):453–461. doi:10.3201/eid2403.170769.
  • Djennad A, Ramsay ME, Pebody R, et al. Effectiveness of 23-valent polysaccharide pneumococcal vaccine and changes in invasive pneumococcal disease incidence from 2000 to 2017 in those aged 65 and over in England and Wales. E Clinical Medicine. 2018 Dec;6:42–50.
  • Shimbashi R, Chang B, Tanabe Y, et al. Epidemiological and clinical features of invasive pneumococcal disease caused by serotype 12F in adults, Japan. PLoS One. 2019;14(2):e0212418.
  • Kawakami K, Nakamura A, Wakana A, et al. A Japanese nationwide survey of 23-valent pneumococcal capsular polysaccharide vaccine (PPSV23) coverage among patients with chronic medical condition aged 50 and older. Hum Vaccin Immunother. 2020 Dec 4;16(7): 1521–1528.
  • Blaabjerg AK, Schumacher AH, Kantso B, et al. Recurrent invasive pneumococcal disease serotype 12F in a vaccinated splenectomized patient. Eur J Microbiol Immunol (Bp. 2016 Mar;6(1):81–84.
  • Chen M, Hisatomi Y, Furumoto A, et al. Comparative immune responses of patients with chronic pulmonary diseases during the 2-year period after pneumococcal vaccination. Clin Vaccine Immunol. 2007 Feb;14(2):139–145.
  • Andrews NJ, Waight PA, George RC, et al. Impact and effectiveness of 23-valent pneumococcal polysaccharide vaccine against invasive pneumococcal disease in the elderly in England and Wales. Vaccine. 2012 Nov 6;30(48):6802–6808.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.